SANUWAVE Health Declares Non-Reliance on Past Financials, Plans Restatement Due to Tax Liabilities

summarizeSummary

SANUWAVE Health announced that investors should no longer rely on its previously issued financial statements for multiple periods in 2024 and 2025, citing newly identified historical sales and use tax liabilities that will require a restatement.

check_boxKey Events

• Non-Reliance Declared

  The company's audit committee, management, and auditors concluded that previously issued unaudited and audited financial statements for multiple periods in 2024 and 2025 should no longer be relied upon.

• Restatement Planned

  SANUWAVE Health plans to restate its consolidated financial statements for the year ended December 31, 2024, and include restated unaudited financial information for other affected periods in its upcoming 2025 Form 10-K.

• Tax Liability Identified

  The non-reliance is due to the identification of historical state sales and use tax liabilities following a third-party nexus study.

• Significant Financial Impact

  The company expects an aggregate increase in reported liabilities of $4.9 million to $5.2 million as of December 31, 2025, and an aggregate increase in expenses of $1.6 million to $1.8 million for 2024 and $1.7 million to $1.9 million for 2025.

auto_awesomeAnalysis

This 8-K filing signals a significant blow to investor confidence as SANUWAVE Health has determined that its financial statements for several past periods, including the audited 2024 annual report, are unreliable. The issue stems from previously unrecognized state sales and use tax liabilities, which are expected to increase reported liabilities by approximately $4.9 million to $5.2 million and expenses by $3.3 million to $3.7 million across 2024 and 2025. The company is also evaluating whether this issue will lead to the identification of additional material weaknesses in its internal control over financial reporting. This development, occurring while the stock trades near its 52-week low, raises serious concerns about the company's accounting practices and financial transparency, potentially leading to increased scrutiny and negative market reaction. Investors should anticipate the restatement in the upcoming 2025 Form 10-K and monitor for further disclosures regarding internal control deficiencies.